IP Library Granted Patent US 12,208,074
Granted Patent B2
US 12,208,074 · App. 17/215,993 · Granted Jan 28, 2025

Butyrate and beta-hydroxybutyrate compositions

Inventor: Franco Cavaleri (Surrrey, CA)
A61K31/19A61K36/82A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,074
App. No.
17/215,993
Granted
Jan 28, 2025
Kind
B2
Abstract

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Claims (11)

1. A composition comprising:

(a) purified butyrate or esters or salts thereof, wherein the purified butyrate includes a butyrate sodium salt, a butyrate calcium salt, or a butyrate magnesium salt; and

(b) purified beta-hydroxybutyrate or esters or salts thereof, wherein the purified beta-hydroxybutyrate includes a beta-hydroxybutyrate sodium salt, a beta-hydroxybutyrate calcium salt, or a beta-hydroxybutyrate magnesium salt, wherein the composition is packaged in a form selected from the group consisting of (i) an oral capsule, (ii) in powdered form, (iii) in an aqueous or non-aqueous liquid, (iv) in an oil-in-water or water-in-oil emulsion, (v) in an elixir or syrup, or (vi) in a paste, wherein the composition is effective to deliver at least 50 mg of a short chain fatty acid and at least 50 mg of ketone to a person on a daily basis.

2. The composition of claim 1 , wherein the composition is effective to deliver at least 200 mg of short chain fatty acid and at least 200 mg of ketone to the person on a daily basis.

3. The composition of claim 1 , wherein the composition is effective to deliver at least 400 mg of short chain fatty acid and at least 400 mg of ketone to the person on a daily basis.

4. The composition of claim 1 , wherein the composition is effective to deliver at least 600 mg of short chain fatty acid and at least 600 mg of ketone to the person on a daily basis.

5. The composition of claim 1 , wherein the composition is effective to deliver at least 800 mg of short chain fatty acid and at least 800 mg of ketone to the person on a daily basis.

6. The composition of claim 1 , which further comprises an agent selected from the group consisting of acetyl-L carnitine, R-alpha lipoic acid, and green tea extract.

7. The composition of claim 1 , which further comprises one or more vitamins.

8. The composition of claim 1 , which further comprises one or more preservatives.

9. The composition of claim 1 , wherein the total purified butyrate to total purified beta-hydroxybutyrate ratio is about 1:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2023
From: CAVALERI, FRANCO
To: CAVALERI HEALTH, INC.
Reel/Frame 064017/0018 →
Continuity (4)
Continuation In Part 16458233 · Jul 1, 2019
Continuation 15187823 · Jun 21, 2016
Provisional Application 62317607 · Apr 3, 2016
Related Publication 20210220302A1 · Jul 22, 2021
References Cited (9)
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 10376482B2 · Cavaleri · 2019 [cited by examiner]
US 10987326B2 · Cavaleri · 2021 [cited by examiner]
WO WO2014153416A1 · 2014 [cited by applicant]
“Keto Os Chocolate Swirl Mocha”: Ingredients, http://myketorecipes.com/recipe/keto-os-chocolate-swirl-mocha/, Feb. 15, 2017 (Feb. 15, 2017). [cited by applicant]
Derr et al., “Suppression of an ethanol withdrawal syndrome in rats by butyrate, lactate and ß-hydroxybutyrate”, Life Sciences, 1983, 32(22), 2551-2554. [cited by applicant]
Stilling et al., “The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis?”, Neurochemistry International 99, 2016, 110-132. [cited by applicant]
Chriett et al., “Essential roles of four-carbon backbone chemicals in the control of metabolism”, World J Biol Chem Aug. 26, 2015, 6(3), 223-230. [cited by applicant]
Canani et al., “Potential beneficial effects of butyrate in intestinal and extraintestinal diseases”, World Journal of Gastroenterology, 2011, 17(12), 1519-1528. [cited by applicant]